Pharmacotherapies for Gaucher disease: what's new on the horizon?

  • Published on 05/29/2026
  •  Reading time: 1 min.

Maya Bhattiprolu a,* , Max Kappler a,* , Tae-Un Han a , Mark Henderson b , Yonatan Serlin a,c & Ellen Sidransky a,*

a Section on Molecular Neurogenetics, National Human Genome Research Institute, National Institutes for Health, Bethesda, MD, USA
b Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA
c National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA

CONTACT Ellen Sidransky mailto:ellen.sidransky@nih.gov Section on Molecular Neurogenetics, National Human Genome Research Institute, National Institutes for Health, Bld 35A, Room 1E 623, 35A Convent Drive, Bethesda, MD 20892-3708, USA

ContentGeneMD

To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Rare Diseases

Receive our newsletter to stay up to date with the latest news in Rare Diseases